<a href="https://www.bioaccessla.com/blog/7-essential-first-in-human-study-designs-you-must-understand" rel="noopener noreferrer" target="_blank">First-in-human trials</a> are the first stage of testing a new drug or device in humans, designed to evaluate safety, tolerability, and initial dosing. Using study designs like single-ascending dose (SAD) and multiple-ascending dose (MAD), these trials provide vital early data that guide all later clinical development.

First-in-human trials are the first stage of testing a new drug or device in humans, designed to evaluate safety, tolerability, and initial dosing. Using study designs like single-ascending dose (SAD) and multiple-ascending dose (MAD), these trials provide vital early data that guide all later clinical development.

First-in-Human Trials: The Foundation of Clinical Development

<a href="https://www.bioaccessla.com/blog/7-essential-first-in-human-study-designs-you-must-understand" rel="noopener noreferrer" target="_blank">First-in-human (FIH) trials</a> mark the first time a new drug or medical device is given to humans — a critical step bridging preclinical work and broader clinical testing. FIH trials primarily aim to assess safety, tolerability, pharmacokinetics, and dosage, often using small cohorts of healthy volunteers. Common designs are single-ascending dose (SAD) studies, where one dose is given then increased in successive groups, and multiple-ascending dose (MAD) studies, where repeated doses are administered over time. Well-designed FIH trials gather early data on how the investigational product behaves in humans, enabling developers to make informed decisions about further clinical phases while minimizing risks for participants.

First-in-human (FIH) trials mark the first time a new drug or medical device is given to humans — a critical step bridging preclinical work and broader clinical testing. FIH trials primarily aim to assess safety, tolerability, pharmacokinetics, and dosage, often using small cohorts of healthy volunteers. Common designs are single-ascending dose (SAD) studies, where one dose is given then increased in successive groups, and multiple-ascending dose (MAD) studies, where repeated doses are administered over time. Well-designed FIH trials gather early data on how the investigational product behaves in humans, enabling developers to make informed decisions about further clinical phases while minimizing risks for participants. 

About

First-in-Human Trials: The Foundation of Clinical Development